8 recruiting, 5 completed, 1 active not recruiting, 1 terminated. 6 Phase 2, 3 Phase 1, 2 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 4, Completed 1, Withdrawn 1 |
| Phase 1 | 3 | Recruiting 2, Active not recruiting 1 |
| Not applicable | 2 | Completed 2 |
| Phase 4 | 1 | Completed 1 |
Follow HPV-Related Malignancy: new trials by email Literature Review of HPV-Related Malignancy trials Research Report on HPV-Related Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer PRGN-2009 plus Pembrolizumab - Cervical Cancer, HPV-Related Carcinoma | Phase 2 | Recruiting | Precigen, Inc | 24 | 2025-11-11 | 2026-04-23 |
| E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers E7 TCR-T cells, Aldesleukin - HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma | Phase 1 / Phase 2 | Recruiting | Christian Hinrichs | 15 | 2025-08-11 | 2026-10-06 |
| Feasibility of HPV Testing With Mail-delivered Sample Collection Kits Mail-based Saliva Sample Kit, Study-related Surveys - HPV Infection, HIV Infections | Recruiting | University of California, San Francisco | 135 | 2024-11-17 | 2026-10-06 | |
| A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors TSC-204-A0201, TSC-204-C0702, TSC-200-A0201 - Head and Neck Cancer, Cervical Cancer | Phase 1 | Active not recruiting | TScan Therapeutics, Inc. | 840 | 2024-05-06 | 2025-11-17 |
| Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. VB10.16, Atezolizumab Injection [Tecentriq], Placebo - HPV-Related Cervical Carcinoma, HPV-Related Malignancy | Phase 2 | Withdrawn | Nykode Therapeutics ASA | 2024-04-18 | 2024-09-20 | |
| SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas SCG142 TCR-T cells - Human Papillomavirus Associated Carcinomas, Cervical Cancer | Phase 1 | Recruiting | The Affiliated Hospital of Qingdao University | 18 | 2023-08-02 | 2024-08-09 |
| Prognostic Value of Conization and Negative HPV After Conization in AIS and Early Stage Cervical Cancer Cervix Cancer, HPV-Related Malignancy | Recruiting | Rambam Health Care Campus | 200 | 2023-07-26 | 2024-01-09 | |
| Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC Non-Interventional, Non-Interventional Follow-up - HIV-Associated Malignant Neoplasm, HIV Infections | Completed | AIDS Malignancy Consortium | 460 | 2023-07-25 | 2026-08-14 | |
| E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers E7 TCR-T cells, Aldesleukin - Cervical Cancer, Throat Cancer | Phase 2 | Recruiting | Christian Hinrichs | 20 | 2023-03-07 | 2026-06-12 |
| A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30 - HPV, Oropharynx Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2022-03-24 | 2026-04-13 |
| The Organ Transplant Recipient HPV and Skin Cancer Study No intervention - Solid Organ Transplant Recipient, Skin Cancer | Recruiting | Merete Haedersdal | 1500 | 2022-03-10 | 2025-04-01 | |
| This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols. Tumor Profiling - Head and Neck Cancer, Melanoma | Terminated | Repertoire Immune Medicines | 22 | 2021-05-05 | 2022-12-06 | |
| Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial Usual Care, Education, Direct Mail - Uterine Cervical Neoplasm, Uterine Neoplasms | Not applicable | Completed | Kaiser Permanente | 32771 | 2020-11-20 | 2023-09-18 |
| IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma IPI-549 - Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Completed | Assuntina G. Sacco, MD | 16 | 2020-03-06 | 2025-07-25 |
| Postpartum HPV Vaccination Gardasil9 - HPV-Related Malignancy | Phase 4 | Completed | University of Alabama at Birmingham | 195 | 2019-04-29 | 2021-10-04 |
| HPV in Blood Samples From Cervical Cancer Patients. Blood sample - HPV-Related Carcinoma, HPV-Related Malignancy | Not applicable | Completed | University of Aarhus | 141 | 2018-06-15 | 2025-04-01 |
Uterine Cervical Neoplasms (11) · Anus Neoplasms (4) · Head and Neck Neoplasms (4) · Neoplasm Metastasis (3) · Neoplasms (3) · Oropharyngeal Neoplasms (3) · Papillomavirus Infections (3) · Penile Neoplasms (3) · Vaginal Neoplasms (3) · Vulvar Neoplasms (3) · HIV Infections (2) · Melanoma (2) · Uterine Cervical Dysplasia (2) · AIDS-related Kaposi sarcoma (1) · Acquired Immunodeficiency Syndrome (1)
Neoplasms by Site (13) · Genital Diseases (12) · Urogenital Diseases (12) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Genital Diseases, Female (11) · Neoplasms (11) · Genital Neoplasms, Female (10) · Urogenital Neoplasms (10) · Uterine Cervical Diseases (10) · Uterine Diseases (10) · Uterine Neoplasms (10) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Anus Diseases (4)
Adoptive Transfer (2) · aldesleukin (2) · Blood Specimen Collection (1) · Chemoradiotherapy (1) · Costs and Cost Analysis (1) · Educational Status (1) · IPI-549 (1) · Radiotherapy, Intensity-Modulated (1) · atezolizumab (1) · pembrolizumab (1)
Christian Hinrichs (2) · AIDS Malignancy Consortium (1) · Assuntina G. Sacco, MD (1) · Kaiser Permanente (1) · Memorial Sloan Kettering Cancer Center (1) · Merete Haedersdal (1) · Nykode Therapeutics ASA (1) · Precigen, Inc (1) · Rambam Health Care Campus (1) · Repertoire Immune Medicines (1) · TScan Therapeutics, Inc. (1) · The Affiliated Hospital of Qingdao University (1) · University of Aarhus (1) · University of Alabama at Birmingham (1) · University of California, San Francisco (1)
United States (11) · Denmark (2) · China (1) · Israel (1) · Puerto Rico (1)
Christian S Hinrichs, MD (2) · Acharf Shamseddine, MD (1) · Alexandra Hernandez Levenston, MD, MPH (1) · Anna E Coghill, PhD, MPH (1) · Beverly B Green, MD, MPH (1) · David Spriggs, MD (1) · Dawn Pinchasik, MD (1) · Ezra Cohen, MD (1) · Rachel L Winer, PhD, MPH (1) · Ritu Salani, MD MBA (1) · Yoav Siegler, MD (1)
PMID 38015219, PMID 41067140, PMID 41653072
R01CA240375 (1), R03DE033930 (1), U01CA287904 (1), UM1CA121947 (1)